 Noel Mueller
Concepts (432)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 20 | 2024 | 503 | 8.190 |
Why?
| | Cesarean Section | 13 | 2023 | 169 | 5.230 |
Why?
| | Microbiota | 14 | 2023 | 651 | 5.000 |
Why?
| | Delivery, Obstetric | 10 | 2022 | 119 | 4.340 |
Why?
| | Adiposity | 10 | 2020 | 467 | 3.000 |
Why?
| | Trace Elements | 4 | 2021 | 48 | 2.890 |
Why?
| | Fatty Acids, Volatile | 7 | 2022 | 47 | 2.730 |
Why?
| | Menarche | 7 | 2023 | 50 | 2.710 |
Why?
| | Body Mass Index | 27 | 2023 | 1982 | 2.660 |
Why?
| | Pre-Eclampsia | 5 | 2022 | 165 | 2.570 |
Why?
| | Hypertension | 10 | 2022 | 1063 | 2.560 |
Why?
| | Pregnancy | 36 | 2023 | 5556 | 2.310 |
Why?
| | Pediatric Obesity | 11 | 2022 | 492 | 2.280 |
Why?
| | Feces | 10 | 2023 | 374 | 2.200 |
Why?
| | Metals, Heavy | 3 | 2021 | 20 | 2.200 |
Why?
| | Prenatal Exposure Delayed Effects | 8 | 2020 | 449 | 2.000 |
Why?
| | Mothers | 13 | 2023 | 667 | 1.970 |
Why?
| | Blood Pressure | 15 | 2022 | 1536 | 1.760 |
Why?
| | Diabetes Mellitus, Type 2 | 13 | 2022 | 2091 | 1.730 |
Why?
| | Vagina | 6 | 2023 | 148 | 1.710 |
Why?
| | Metformin | 5 | 2022 | 278 | 1.630 |
Why?
| | Female | 92 | 2024 | 60086 | 1.610 |
Why?
| | Dietary Fiber | 3 | 2023 | 40 | 1.610 |
Why?
| | Dietary Approaches To Stop Hypertension | 3 | 2020 | 10 | 1.530 |
Why?
| | Fetal Blood | 4 | 2022 | 268 | 1.520 |
Why?
| | Infant, Newborn | 19 | 2023 | 5089 | 1.410 |
Why?
| | Carbonated Beverages | 3 | 2015 | 15 | 1.400 |
Why?
| | Humans | 115 | 2024 | 115908 | 1.360 |
Why?
| | Dietary Carbohydrates | 3 | 2021 | 136 | 1.360 |
Why?
| | Premature Birth | 2 | 2023 | 278 | 1.330 |
Why?
| | Dietary Proteins | 2 | 2020 | 126 | 1.290 |
Why?
| | Cardiovascular Diseases | 9 | 2022 | 1724 | 1.280 |
Why?
| | Obesity | 15 | 2022 | 2530 | 1.280 |
Why?
| | Longevity | 2 | 2019 | 137 | 1.210 |
Why?
| | Infant | 22 | 2023 | 8002 | 1.180 |
Why?
| | Adult | 52 | 2024 | 30820 | 1.140 |
Why?
| | Methylamines | 2 | 2024 | 30 | 1.090 |
Why?
| | Diet | 13 | 2024 | 1075 | 1.080 |
Why?
| | Non-Nutritive Sweeteners | 2 | 2015 | 5 | 1.050 |
Why?
| | Prospective Studies | 21 | 2022 | 6267 | 1.040 |
Why?
| | Anti-Bacterial Agents | 5 | 2020 | 1486 | 0.990 |
Why?
| | Male | 62 | 2024 | 56128 | 0.980 |
Why?
| | Longitudinal Studies | 13 | 2024 | 2437 | 0.970 |
Why?
| | Selenium | 2 | 2021 | 31 | 0.940 |
Why?
| | Bacteria | 5 | 2023 | 731 | 0.930 |
Why?
| | Insulin Resistance | 6 | 2022 | 1078 | 0.920 |
Why?
| | Child | 31 | 2023 | 18555 | 0.910 |
Why?
| | Sugars | 1 | 2023 | 29 | 0.900 |
Why?
| | Infant Nutritional Physiological Phenomena | 3 | 2020 | 133 | 0.900 |
Why?
| | Risk Factors | 30 | 2022 | 8714 | 0.900 |
Why?
| | Manganese | 2 | 2020 | 52 | 0.890 |
Why?
| | Leg | 2 | 2015 | 227 | 0.880 |
Why?
| | Osteoporotic Fractures | 1 | 2023 | 57 | 0.840 |
Why?
| | Blood Pressure Determination | 3 | 2019 | 123 | 0.820 |
Why?
| | Overweight | 10 | 2021 | 468 | 0.820 |
Why?
| | Diet, Mediterranean | 1 | 2022 | 20 | 0.810 |
Why?
| | Chorioamnionitis | 1 | 2021 | 36 | 0.780 |
Why?
| | Cross-Sectional Studies | 15 | 2024 | 4449 | 0.760 |
Why?
| | Hypotension | 1 | 2022 | 116 | 0.750 |
Why?
| | Breast Feeding | 2 | 2023 | 371 | 0.740 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 47 | 0.740 |
Why?
| | Fats, Unsaturated | 1 | 2020 | 1 | 0.720 |
Why?
| | Weight Gain | 3 | 2018 | 455 | 0.710 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2020 | 21 | 0.700 |
Why?
| | Diet, Sodium-Restricted | 2 | 2019 | 32 | 0.700 |
Why?
| | Body Fluids | 1 | 2019 | 58 | 0.690 |
Why?
| | Flatulence | 1 | 2019 | 2 | 0.680 |
Why?
| | Dyspepsia | 1 | 2019 | 9 | 0.680 |
Why?
| | Cohort Studies | 13 | 2023 | 4960 | 0.670 |
Why?
| | Middle Aged | 35 | 2024 | 27084 | 0.660 |
Why?
| | Androgens | 1 | 2020 | 165 | 0.660 |
Why?
| | Milk, Human | 1 | 2020 | 128 | 0.660 |
Why?
| | Pressure | 1 | 2020 | 218 | 0.650 |
Why?
| | Abdominal Pain | 1 | 2020 | 137 | 0.640 |
Why?
| | Vitamin D Deficiency | 1 | 2020 | 159 | 0.640 |
Why?
| | HTLV-I Infections | 8 | 2000 | 21 | 0.630 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2020 | 492 | 0.630 |
Why?
| | Vitamin D | 2 | 2023 | 341 | 0.630 |
Why?
| | Disinfectants | 1 | 2018 | 34 | 0.620 |
Why?
| | Boston | 6 | 2021 | 76 | 0.620 |
Why?
| | Waist Circumference | 4 | 2016 | 123 | 0.610 |
Why?
| | Estrogens | 1 | 2020 | 316 | 0.610 |
Why?
| | Young Adult | 18 | 2021 | 10518 | 0.590 |
Why?
| | Weight Loss | 5 | 2022 | 632 | 0.590 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 246 | 0.580 |
Why?
| | Birth Weight | 6 | 2018 | 439 | 0.580 |
Why?
| | Skinfold Thickness | 2 | 2018 | 48 | 0.580 |
Why?
| | Sequence Analysis, DNA | 1 | 2020 | 733 | 0.570 |
Why?
| | Age Factors | 6 | 2020 | 2912 | 0.570 |
Why?
| | Rural Population | 3 | 2018 | 449 | 0.550 |
Why?
| | Adolescent | 23 | 2022 | 17955 | 0.550 |
Why?
| | Puberty | 2 | 2014 | 137 | 0.540 |
Why?
| | Gastrointestinal Tract | 2 | 2015 | 169 | 0.540 |
Why?
| | Singapore | 5 | 2013 | 15 | 0.520 |
Why?
| | Asthma | 3 | 2022 | 2152 | 0.500 |
Why?
| | Child, Preschool | 12 | 2023 | 9175 | 0.500 |
Why?
| | Infant Welfare | 1 | 2014 | 4 | 0.500 |
Why?
| | Brazil | 7 | 2016 | 105 | 0.490 |
Why?
| | Leptin | 1 | 2016 | 211 | 0.480 |
Why?
| | Abdominal Fat | 1 | 2014 | 43 | 0.480 |
Why?
| | Adiponectin | 1 | 2016 | 213 | 0.480 |
Why?
| | Health Status | 2 | 2023 | 733 | 0.470 |
Why?
| | Metabolic Syndrome | 4 | 2021 | 323 | 0.460 |
Why?
| | Diabetes, Gestational | 2 | 2018 | 274 | 0.460 |
Why?
| | Chronic Disease | 1 | 2019 | 1602 | 0.450 |
Why?
| | Baltimore | 2 | 2024 | 43 | 0.450 |
Why?
| | Feeding Behavior | 2 | 2017 | 573 | 0.450 |
Why?
| | Glucose | 2 | 2015 | 904 | 0.450 |
Why?
| | Social Class | 1 | 2015 | 213 | 0.440 |
Why?
| | Fetal Development | 1 | 2016 | 248 | 0.440 |
Why?
| | Dyslipidemias | 1 | 2015 | 155 | 0.440 |
Why?
| | Aged | 19 | 2024 | 19299 | 0.440 |
Why?
| | Linear Models | 6 | 2018 | 778 | 0.430 |
Why?
| | Parity | 1 | 2013 | 99 | 0.430 |
Why?
| | Wrist | 1 | 2013 | 49 | 0.430 |
Why?
| | Anthropometry | 1 | 2013 | 182 | 0.430 |
Why?
| | Social Determinants of Health | 1 | 2015 | 138 | 0.420 |
Why?
| | Liver | 1 | 2020 | 1693 | 0.420 |
Why?
| | Bayes Theorem | 4 | 2021 | 336 | 0.420 |
Why?
| | Fatty Liver | 1 | 2014 | 217 | 0.420 |
Why?
| | Soy Foods | 1 | 2011 | 3 | 0.400 |
Why?
| | Soybean Proteins | 1 | 2011 | 10 | 0.400 |
Why?
| | Isoflavones | 1 | 2011 | 16 | 0.400 |
Why?
| | Gestational Age | 3 | 2021 | 757 | 0.400 |
Why?
| | Micronutrients | 2 | 2023 | 77 | 0.400 |
Why?
| | Intra-Abdominal Fat | 1 | 2012 | 84 | 0.400 |
Why?
| | Butyrates | 2 | 2022 | 53 | 0.380 |
Why?
| | Obesity, Abdominal | 3 | 2016 | 38 | 0.370 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 528 | 0.360 |
Why?
| | Time Factors | 6 | 2020 | 6186 | 0.360 |
Why?
| | Bifidobacterium | 2 | 2021 | 21 | 0.350 |
Why?
| | Probiotics | 2 | 2021 | 47 | 0.350 |
Why?
| | Emigrants and Immigrants | 1 | 2012 | 111 | 0.350 |
Why?
| | Child Health | 2 | 2023 | 134 | 0.340 |
Why?
| | Follow-Up Studies | 8 | 2018 | 4446 | 0.330 |
Why?
| | Metabolome | 2 | 2022 | 286 | 0.330 |
Why?
| | Socioeconomic Factors | 6 | 2021 | 1090 | 0.330 |
Why?
| | Protective Factors | 3 | 2019 | 87 | 0.320 |
Why?
| | Papillomavirus Vaccines | 1 | 2012 | 222 | 0.320 |
Why?
| | Papillomavirus Infections | 1 | 2012 | 258 | 0.320 |
Why?
| | Quality of Life | 1 | 2019 | 2392 | 0.310 |
Why?
| | Absorptiometry, Photon | 2 | 2023 | 221 | 0.310 |
Why?
| | Beverages | 2 | 2023 | 59 | 0.310 |
Why?
| | Case-Control Studies | 6 | 2023 | 3054 | 0.300 |
Why?
| | Women, Working | 2 | 2017 | 9 | 0.300 |
Why?
| | Risk Assessment | 4 | 2020 | 3004 | 0.300 |
Why?
| | Logistic Models | 7 | 2023 | 1865 | 0.300 |
Why?
| | Air Pollution | 2 | 2020 | 183 | 0.280 |
Why?
| | Incidence | 7 | 2022 | 2333 | 0.280 |
Why?
| | Prevalence | 9 | 2019 | 2270 | 0.280 |
Why?
| | Interviews as Topic | 3 | 2015 | 594 | 0.280 |
Why?
| | Body Size | 2 | 2018 | 92 | 0.270 |
Why?
| | Blood Glucose | 5 | 2021 | 1826 | 0.270 |
Why?
| | Sleep | 2 | 2023 | 626 | 0.260 |
Why?
| | Infant, Low Birth Weight | 2 | 2016 | 125 | 0.260 |
Why?
| | Emergency Medical Services | 1 | 2012 | 591 | 0.240 |
Why?
| | Ohio | 2 | 2015 | 136 | 0.240 |
Why?
| | Diet, Vegetarian | 1 | 2024 | 6 | 0.230 |
Why?
| | Research Design | 2 | 2021 | 947 | 0.230 |
Why?
| | Homeostasis | 3 | 2016 | 576 | 0.230 |
Why?
| | Vitamins | 2 | 2023 | 151 | 0.230 |
Why?
| | Severity of Illness Index | 3 | 2020 | 2598 | 0.230 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1193 | 0.220 |
Why?
| | Vitamin A | 1 | 2023 | 52 | 0.220 |
Why?
| | Aging | 2 | 2024 | 1640 | 0.220 |
Why?
| | Nutrition Assessment | 2 | 2015 | 76 | 0.220 |
Why?
| | Maternal Age | 1 | 2023 | 117 | 0.220 |
Why?
| | Pancreatic Neoplasms | 1 | 2010 | 721 | 0.220 |
Why?
| | Phthalic Acids | 1 | 2022 | 28 | 0.210 |
Why?
| | Pregnancy Complications | 2 | 2018 | 431 | 0.210 |
Why?
| | Sodium, Dietary | 2 | 2019 | 36 | 0.210 |
Why?
| | District of Columbia | 3 | 2021 | 26 | 0.200 |
Why?
| | Epidemiologic Studies | 1 | 2022 | 58 | 0.200 |
Why?
| | Sodium | 2 | 2021 | 182 | 0.200 |
Why?
| | Obesity Management | 1 | 2021 | 8 | 0.200 |
Why?
| | Sex Characteristics | 2 | 2016 | 644 | 0.200 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2021 | 38 | 0.200 |
Why?
| | Regression Analysis | 3 | 2012 | 961 | 0.200 |
Why?
| | Glycemic Index | 1 | 2021 | 21 | 0.200 |
Why?
| | Permeability | 1 | 2022 | 151 | 0.200 |
Why?
| | Purines | 1 | 2022 | 159 | 0.190 |
Why?
| | Cardiovascular System | 1 | 2023 | 124 | 0.190 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 89 | 0.190 |
Why?
| | Clostridium perfringens | 1 | 2021 | 5 | 0.190 |
Why?
| | Clostridium | 1 | 2021 | 14 | 0.190 |
Why?
| | Bacteroides | 1 | 2021 | 16 | 0.190 |
Why?
| | Oxides | 1 | 2021 | 43 | 0.190 |
Why?
| | Environmental Pollutants | 1 | 2022 | 112 | 0.190 |
Why?
| | Smoking | 4 | 2013 | 1468 | 0.190 |
Why?
| | Growth | 1 | 2021 | 56 | 0.190 |
Why?
| | Folic Acid | 2 | 2023 | 159 | 0.190 |
Why?
| | Health Impact Assessment | 1 | 2020 | 8 | 0.180 |
Why?
| | Minority Groups | 1 | 2022 | 232 | 0.180 |
Why?
| | Postpartum Period | 1 | 2023 | 281 | 0.180 |
Why?
| | Pregnancy Trimester, First | 1 | 2021 | 129 | 0.180 |
Why?
| | Odds Ratio | 6 | 2023 | 969 | 0.180 |
Why?
| | Uric Acid | 1 | 2021 | 150 | 0.180 |
Why?
| | Sex Factors | 4 | 2019 | 1741 | 0.180 |
Why?
| | Massachusetts | 1 | 2020 | 138 | 0.180 |
Why?
| | Dysbiosis | 1 | 2021 | 145 | 0.180 |
Why?
| | Vulnerable Populations | 1 | 2021 | 137 | 0.180 |
Why?
| | DNA, Ribosomal | 1 | 2020 | 80 | 0.180 |
Why?
| | Skin Absorption | 1 | 2019 | 13 | 0.180 |
Why?
| | HTLV-I Antibodies | 4 | 1992 | 5 | 0.180 |
Why?
| | United States | 8 | 2023 | 12338 | 0.180 |
Why?
| | Appetite | 1 | 2020 | 53 | 0.170 |
Why?
| | Interdisciplinary Research | 1 | 2020 | 25 | 0.170 |
Why?
| | Digestive System | 1 | 2019 | 27 | 0.170 |
Why?
| | Mercury | 1 | 2019 | 29 | 0.170 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2021 | 281 | 0.170 |
Why?
| | Hepatitis C | 2 | 2000 | 229 | 0.170 |
Why?
| | Cadmium | 1 | 2019 | 58 | 0.170 |
Why?
| | Lead | 1 | 2019 | 43 | 0.170 |
Why?
| | Employment | 2 | 2017 | 139 | 0.170 |
Why?
| | Cholesterol, HDL | 1 | 2020 | 185 | 0.170 |
Why?
| | Behavior Therapy | 1 | 2021 | 227 | 0.170 |
Why?
| | Venezuela | 1 | 2018 | 7 | 0.160 |
Why?
| | Men's Health | 1 | 2018 | 7 | 0.160 |
Why?
| | Infectious Mononucleosis | 1 | 1998 | 8 | 0.160 |
Why?
| | United States Food and Drug Administration | 1 | 2019 | 173 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2021 | 208 | 0.160 |
Why?
| | Surveys and Questionnaires | 4 | 2014 | 4670 | 0.160 |
Why?
| | Age Distribution | 2 | 2018 | 341 | 0.160 |
Why?
| | DNA, Bacterial | 1 | 2020 | 308 | 0.160 |
Why?
| | Skin | 1 | 2023 | 668 | 0.160 |
Why?
| | Dizziness | 1 | 2019 | 70 | 0.160 |
Why?
| | Biomarkers | 4 | 2022 | 3474 | 0.160 |
Why?
| | Lipopolysaccharides | 1 | 2022 | 832 | 0.160 |
Why?
| | Age of Onset | 2 | 2016 | 455 | 0.160 |
Why?
| | Cholesterol, LDL | 1 | 2020 | 309 | 0.160 |
Why?
| | Herpesvirus 4, Human | 1 | 1998 | 123 | 0.150 |
Why?
| | Nutrition Surveys | 2 | 2021 | 225 | 0.150 |
Why?
| | Liver Neoplasms | 2 | 2000 | 521 | 0.150 |
Why?
| | Computational Biology | 1 | 2021 | 528 | 0.150 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2018 | 64 | 0.150 |
Why?
| | Reference Values | 1 | 2019 | 745 | 0.150 |
Why?
| | Infant, Small for Gestational Age | 1 | 2018 | 75 | 0.150 |
Why?
| | Leukocytes | 1 | 2018 | 284 | 0.140 |
Why?
| | Developing Countries | 2 | 2017 | 242 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 945 | 0.140 |
Why?
| | Verrucomicrobia | 1 | 2016 | 6 | 0.140 |
Why?
| | Hodgkin Disease | 1 | 1998 | 118 | 0.140 |
Why?
| | Colombia | 2 | 2016 | 42 | 0.140 |
Why?
| | Public Health | 1 | 2021 | 439 | 0.140 |
Why?
| | Maternal Exposure | 1 | 2018 | 137 | 0.140 |
Why?
| | Income | 1 | 2017 | 170 | 0.140 |
Why?
| | Confidence Intervals | 2 | 2012 | 310 | 0.140 |
Why?
| | Death | 1 | 2017 | 107 | 0.140 |
Why?
| | Particulate Matter | 1 | 2018 | 217 | 0.140 |
Why?
| | Phylogeny | 1 | 2020 | 802 | 0.140 |
Why?
| | Pandemics | 2 | 2021 | 1333 | 0.130 |
Why?
| | Autism Spectrum Disorder | 1 | 2020 | 323 | 0.130 |
Why?
| | Preconception Care | 1 | 2016 | 30 | 0.130 |
Why?
| | Aspartame | 1 | 2015 | 3 | 0.130 |
Why?
| | Intestines | 1 | 2018 | 325 | 0.130 |
Why?
| | Japan | 4 | 2000 | 89 | 0.130 |
Why?
| | Coffee | 1 | 2015 | 11 | 0.130 |
Why?
| | China | 1 | 2015 | 168 | 0.120 |
Why?
| | Caffeine | 1 | 2015 | 58 | 0.120 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 155 | 0.120 |
Why?
| | Nutrition Policy | 1 | 2015 | 54 | 0.120 |
Why?
| | Body Weight | 1 | 2019 | 872 | 0.120 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2015 | 97 | 0.120 |
Why?
| | Organ Size | 1 | 2015 | 435 | 0.120 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1088 | 0.120 |
Why?
| | Prognosis | 2 | 2019 | 3342 | 0.120 |
Why?
| | Animals | 6 | 2023 | 32123 | 0.120 |
Why?
| | California | 1 | 2015 | 369 | 0.120 |
Why?
| | Physical Examination | 1 | 2015 | 224 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2019 | 1096 | 0.110 |
Why?
| | Epidemiologic Methods | 1 | 2013 | 73 | 0.110 |
Why?
| | Nutritional Status | 1 | 2015 | 287 | 0.110 |
Why?
| | Glucose Metabolism Disorders | 1 | 2012 | 10 | 0.110 |
Why?
| | Diabetic Angiopathies | 1 | 2014 | 243 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1444 | 0.100 |
Why?
| | Central America | 1 | 2012 | 18 | 0.100 |
Why?
| | Abdomen | 1 | 2012 | 106 | 0.100 |
Why?
| | South America | 1 | 2012 | 55 | 0.100 |
Why?
| | Brain | 1 | 2023 | 2382 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2015 | 1226 | 0.100 |
Why?
| | Area Under Curve | 1 | 2012 | 277 | 0.100 |
Why?
| | Demography | 3 | 2017 | 264 | 0.090 |
Why?
| | ROC Curve | 1 | 2012 | 451 | 0.090 |
Why?
| | Cytokines | 1 | 2018 | 1857 | 0.090 |
Why?
| | Occupations | 3 | 2017 | 37 | 0.090 |
Why?
| | Dietary Sucrose | 1 | 2010 | 45 | 0.090 |
Why?
| | Diabetes Mellitus | 2 | 2016 | 906 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2021 | 9166 | 0.080 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2012 | 213 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1008 | 0.080 |
Why?
| | Dietary Supplements | 2 | 2023 | 460 | 0.080 |
Why?
| | Health Promotion | 1 | 2015 | 690 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1817 | 0.080 |
Why?
| | India | 2 | 2021 | 135 | 0.080 |
Why?
| | Patient Selection | 1 | 2011 | 656 | 0.070 |
Why?
| | Smoking Cessation | 1 | 2011 | 378 | 0.070 |
Why?
| | Human T-lymphotropic virus 1 | 2 | 1999 | 23 | 0.070 |
Why?
| | Nucleoside-Triphosphatase | 1 | 2006 | 4 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2015 | 1459 | 0.070 |
Why?
| | Mice | 1 | 2022 | 15075 | 0.070 |
Why?
| | RNA Helicases | 1 | 2006 | 20 | 0.070 |
Why?
| | Flavivirus | 1 | 2006 | 16 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2012 | 771 | 0.070 |
Why?
| | Lipids | 2 | 2022 | 589 | 0.060 |
Why?
| | Waist-Hip Ratio | 2 | 2016 | 30 | 0.060 |
Why?
| | Viral Nonstructural Proteins | 1 | 2006 | 56 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2409 | 0.060 |
Why?
| | Insulin | 3 | 2021 | 2083 | 0.060 |
Why?
| | Retrospective Studies | 3 | 2018 | 12616 | 0.060 |
Why?
| | Registries | 1 | 2012 | 1773 | 0.060 |
Why?
| | Vegetables | 1 | 2023 | 129 | 0.050 |
Why?
| | Iron | 1 | 2023 | 235 | 0.050 |
Why?
| | Heartburn | 1 | 2021 | 11 | 0.050 |
Why?
| | Maryland | 1 | 2021 | 37 | 0.050 |
Why?
| | American Heart Association | 1 | 2023 | 266 | 0.050 |
Why?
| | Nutritional Requirements | 1 | 2021 | 71 | 0.050 |
Why?
| | Hunger | 1 | 2021 | 39 | 0.050 |
Why?
| | Gout | 1 | 2021 | 37 | 0.050 |
Why?
| | Body Composition | 2 | 2015 | 581 | 0.050 |
Why?
| | City Planning | 1 | 2020 | 1 | 0.050 |
Why?
| | Africa, Eastern | 1 | 2020 | 10 | 0.050 |
Why?
| | Transportation | 1 | 2020 | 44 | 0.040 |
Why?
| | Causality | 1 | 2020 | 106 | 0.040 |
Why?
| | Cities | 1 | 2020 | 90 | 0.040 |
Why?
| | Capital Financing | 1 | 2020 | 5 | 0.040 |
Why?
| | Tuberculin | 1 | 1999 | 6 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2021 | 185 | 0.040 |
Why?
| | Mentoring | 1 | 2021 | 103 | 0.040 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 76 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2022 | 381 | 0.040 |
Why?
| | Lipoproteins, LDL | 1 | 2019 | 129 | 0.040 |
Why?
| | Meconium | 1 | 2018 | 7 | 0.040 |
Why?
| | Viral Matrix Proteins | 1 | 1998 | 22 | 0.040 |
Why?
| | Oncogene Proteins, Viral | 1 | 1998 | 20 | 0.040 |
Why?
| | Th1 Cells | 1 | 1999 | 125 | 0.040 |
Why?
| | Diet, Western | 1 | 2019 | 66 | 0.040 |
Why?
| | Virus Latency | 1 | 1998 | 80 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2018 | 77 | 0.040 |
Why?
| | Cholesterol | 1 | 2019 | 367 | 0.040 |
Why?
| | Cancer Survivors | 1 | 2021 | 203 | 0.040 |
Why?
| | Metabolic Diseases | 1 | 2018 | 99 | 0.040 |
Why?
| | Calcium | 1 | 2023 | 1102 | 0.040 |
Why?
| | Immunologic Memory | 1 | 1999 | 312 | 0.040 |
Why?
| | Sex Distribution | 2 | 2014 | 338 | 0.040 |
Why?
| | Triglycerides | 1 | 2019 | 470 | 0.040 |
Why?
| | Mucins | 1 | 2016 | 62 | 0.030 |
Why?
| | Sarcoma, Kaposi | 1 | 1997 | 69 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1149 | 0.030 |
Why?
| | Deltaretrovirus Antibodies | 1 | 1996 | 1 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2018 | 281 | 0.030 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2016 | 48 | 0.030 |
Why?
| | Health Care Costs | 1 | 2019 | 386 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 336 | 0.030 |
Why?
| | Health Behavior | 1 | 2021 | 707 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2019 | 480 | 0.030 |
Why?
| | Health Surveys | 1 | 2017 | 449 | 0.030 |
Why?
| | Disease Transmission, Infectious | 1 | 1996 | 57 | 0.030 |
Why?
| | Educational Status | 1 | 2017 | 429 | 0.030 |
Why?
| | Carrier State | 1 | 1996 | 55 | 0.030 |
Why?
| | RNA, Viral | 1 | 1998 | 561 | 0.030 |
Why?
| | Dominican Republic | 1 | 2015 | 18 | 0.030 |
Why?
| | Aged, 80 and over | 4 | 1997 | 6438 | 0.030 |
Why?
| | New York | 1 | 2015 | 110 | 0.030 |
Why?
| | Gene Products, tax | 2 | 1991 | 9 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2014 | 44 | 0.030 |
Why?
| | Hepatitis B | 1 | 1995 | 53 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2015 | 123 | 0.030 |
Why?
| | Communication | 1 | 2020 | 749 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1216 | 0.030 |
Why?
| | Poverty | 1 | 2017 | 444 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2015 | 344 | 0.030 |
Why?
| | Colorado | 1 | 2023 | 4122 | 0.030 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1995 | 224 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1728 | 0.030 |
Why?
| | Serologic Tests | 1 | 1992 | 51 | 0.030 |
Why?
| | Forestry | 1 | 1992 | 4 | 0.030 |
Why?
| | Fisheries | 1 | 1992 | 3 | 0.030 |
Why?
| | Leukemia, T-Cell | 1 | 1991 | 4 | 0.030 |
Why?
| | DNA | 1 | 2018 | 1358 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2015 | 295 | 0.020 |
Why?
| | Toxoplasmosis | 1 | 1992 | 31 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 2814 | 0.020 |
Why?
| | Agriculture | 1 | 1992 | 76 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 1761 | 0.020 |
Why?
| | Sexually Transmitted Diseases | 1 | 1991 | 154 | 0.020 |
Why?
| | Neoplasms | 1 | 2021 | 2112 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 2861 | 0.020 |
Why?
| | Health Personnel | 1 | 1992 | 578 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 2006 | 2793 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2006 | 352 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 1999 | 1243 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2000 | 0.010 |
Why?
| | Tritium | 1 | 1999 | 69 | 0.010 |
Why?
| | Mycobacterium bovis | 1 | 1999 | 11 | 0.010 |
Why?
| | BCG Vaccine | 1 | 1999 | 18 | 0.010 |
Why?
| | Thymidine | 1 | 1999 | 58 | 0.010 |
Why?
| | Interleukin-12 | 1 | 1999 | 110 | 0.010 |
Why?
| | Antigens, Bacterial | 1 | 1999 | 112 | 0.010 |
Why?
| | Antigens, Viral | 1 | 1999 | 174 | 0.010 |
Why?
| | Interleukin-2 | 1 | 1999 | 414 | 0.010 |
Why?
| | Blotting, Western | 2 | 1991 | 1153 | 0.010 |
Why?
| | Cell Division | 1 | 1999 | 760 | 0.010 |
Why?
| | Greece | 1 | 1997 | 7 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1999 | 731 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1997 | 221 | 0.010 |
Why?
| | Hepatitis Antibodies | 1 | 1995 | 1 | 0.010 |
Why?
| | Hepatitis B Surface Antigens | 1 | 1995 | 19 | 0.010 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 1995 | 14 | 0.010 |
Why?
| | Hepatitis B virus | 1 | 1995 | 25 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 1995 | 141 | 0.010 |
Why?
| | Eye Diseases | 1 | 1995 | 76 | 0.010 |
Why?
| | Hepacivirus | 1 | 1995 | 234 | 0.010 |
Why?
| | Life Style | 1 | 1995 | 428 | 0.010 |
Why?
| | Blood Transfusion | 1 | 1995 | 277 | 0.010 |
Why?
| | Retroviruses, Simian | 1 | 1991 | 1 | 0.010 |
Why?
| | HTLV-I Antigens | 1 | 1991 | 1 | 0.010 |
Why?
| | Genes, pX | 1 | 1991 | 2 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1999 | 3916 | 0.010 |
Why?
| | Papio | 1 | 1991 | 96 | 0.010 |
Why?
| | Agglutination Tests | 1 | 1991 | 2 | 0.010 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 1990 | 6 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1991 | 163 | 0.010 |
Why?
| | Lymphocytes | 1 | 1991 | 342 | 0.010 |
Why?
| | DNA, Viral | 1 | 1991 | 351 | 0.010 |
Why?
| | Antibody Formation | 1 | 1991 | 273 | 0.010 |
Why?
| | Alcohol Drinking | 1 | 1995 | 654 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1991 | 1001 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 794 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1991 | 520 | 0.000 |
Why?
| | Family | 1 | 1991 | 591 | 0.000 |
Why?
| | Base Sequence | 1 | 1991 | 2120 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2167 | 0.000 |
Why?
|
|
Mueller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|